Methotrexate, a traditional DMARD, is one of the gold standards of therapy for RA that restores defective Treg function through demethylation of the Foxp3 locus, leading to subsequent facilitates in Foxp3 and CTLA-4 expression (Cribbs et al., 2015). Here, CTLA4 is linked to rheumatoid arthritis.